Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity

European Neuropsychopharmacology

Volumn 16, Issue SUPPL. 3, 2006, Pages

  Van Gaal, Luc F ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Abdominal adiposity; Atypical antipsychotic; Cardiovascular disease; Metabolic syndrome; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; HEREDITY; HUMAN; HYPERTENSION; LIFESTYLE; LIPID ANALYSIS; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ABDOMINAL FAT; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; LONG-TERM CARE; METABOLIC DISEASES; RISK FACTORS; SCHIZOPHRENIA;

EID: 33746848948     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.06.005     Document Type: Article

References (34)

1. ADA/APA/AACE/NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care 27 (2004) 596-601
2. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chandler L.P., Weiden P.J., and Cheskin L.J. The distribution of body mass index among individuals with and without schizophrenia. J. Clin. Psychiatry 60 (1999) 215-220
3. Almeras N., Despres J.P., Villeneuve J., Demers M.F., Roy M.A., Cadrin C., Mottard J.P., and Bouchard R.H. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J. Clin. Psychiatry 65 (2004) 557-564
4. Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr. Res. 71 (2004) 445-462
5. Blonde, L., Ray, S., Carson, W., L'Italien, G., 2005. Metabolic syndrome is an important predictor of cardiovascular disease and new onset diabetes. A systematic review of the literature. Abstract presented at the 158th Annual Meeting of the American Psychiatric Association, Atlanta, Georgia. Available from http://www.psych.org/public_info/libr_publ/abstracts.cfm accessed 12 May 2006.
6. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry 171 (1997) 502-508
7. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., Lindenmayer J.P., Manoukian S.V., Banerji M.A., Lebovitz H.E., and Hennekens C.H. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J. Clin. Psychiatry 65 (2004) 4-18
8. Cohn G., Valdes G., and Capuzzi D.M. Pathophysiology and treatment of the dyslipidemia of insulin resistance. Curr. Cardiol. Rep. 3 (2001) 416-423
9. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., and Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26 (2000) 903-912
10. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
11. Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R., Wiedmeyer H.M., and Byrd-Holt D.D. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21 (1998) 518-524
12. Haupt D.W. Differential metabolic effects of antipsychotic treatments. Eur. Neuropsychopharmacol. 16 (2006) S142-S155
13. Heiskanen T., Niskanen L., Lyytikainen R., Saarinen P.I., and Hintikka J. Metabolic syndrome in patients with schizophrenia. J. Clin. Psychiatry 64 (2003) 575-579
14. Hirji I., Ulcickas Yood M., and Bracken M.B. Rates of death among antipsychotic users within a managed care organization. Abstract presented at the 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA (2005). http://www.psych.org/public_info/libr_publ/abstracts.cfm Available from http://www.psych.org/public_info/libr_publ/abstracts.cfm accessed 12 May 2006
15. Kato M.M., Currier B., Gomez C.M., Hall L., and Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim. Care Companion J. Clin. Psychiat. 6 (2004) 74-77
16. Kernan W.N., and Inzucchi S.E. Type 2 diabetes mellitus and insulin resistance: stroke prevention and management. Curr. Treat. Options Neurol. 6 (2004) 443-450
17. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., and Salonen J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
18. Lean M.E., Han T.S., and Morrison C.E. Waist circumference as a measure for indicating need for weight management. BMJ 311 (1995) 158-161
19. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., and Williams G.R. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
20. Morgan C.L., Currie C.J., Stott N.C., Smithers M., Butler C.C., and Peters J.R. The prevalence of multiple diabetes-related complications. Diabet. Med. 17 (2000) 146-151
21. NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
22. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., and Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch. Intern. Med. 163 (2003) 427-436
23. Pouliot M.C., Despres J.P., Lemieux S., Moorjani S., Bouchard C., Tremblay A., Nadeau A., and Lupien P.J. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol. 73 (1994) 460-468
24. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 160 (2003) 284-289
25. Saari K.M., Lindeman S.M., Viilo K.M., Isohanni M.K., Jarvelin M.R., Lauren L.H., Savolainen M.J., and Koponen H.J. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J. Clin. Psychiatry 66 (2005) 559-563
26. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., Isles C., Macfarlane P.W., Packard C.J., Cobbe S.M., and Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
27. Sikich L., Hamer R.M., Bashford R.A., Sheitman B.B., and Lieberman J.A. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29 (2004) 133-145
28. Straker D., Correll C.U., Kramer-Ginsberg E., Abdulhamid N., Koshy F., Rubens E., Saint-Vil R., Kane J.M., and Manu P. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am. J. Psychiatry 162 (2005) 1217-1221
29. Van Gaal L.F., Wauters M.A., and De Leeuw I.H. The beneficial effects of modest weight loss on cardiovascular risk factors. Int. J. Obes. Relat. Metab. Disord. 21 Suppl 1 (1997) S5-S9
30. Vinik A.I., and Vinik E. Prevention of the complications of diabetes. Am. J. Manag. Care 9 (2003) S63-S80 (quiz S81-64)
31. Vora J.P., Ibrahim H.A., and Bakris G.L. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J. Hum. Hypertens. 14 (2000) 667-685
32. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
33. World Federation for Mental Health. Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues [Academic highlights]. Proceedings summary from the World Federation for Mental Health meeting, Sept 29-30, 2004; Vienna, Austria. J. Clin. Psychiatry 66 (2005) 790-798
34. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., and Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952